Gene Editing

Research from this past year highlights the potential of CRISPR-Cas9 technology in modeling and treating rare disease

Transposons have the potential to make DNA editing easier, cheaper, and safer

Researchers have successfully treated a rare genetic immunodeficiency disorder using an investigational gene therapy

The early phase, first-in-human trial aims to correct the sickle mutation in blood stem cells that causes the disease

With the new gene editing technique, researchers can program sequential genome edits over time

Base editors hold great promise for safer multiplex gene editing

The new therapy targets a gene mutation that causes  mitochondrial dysfunction

From discovery and development to clinical applications

ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9

Results of recent experiments are likely to speed up and aid understanding of the DNA activity that typically causes aging and many cancers